Serendex Pharmaceuticals has entered into an exclusive agreement with CMC Biologics to develop and manufacture Factor VIIa, a therapeutic protein with potential applications in treating acute lung bleeding. This partnership is significant for Serendex as it allows them to leverage CMC Biologics' expertise in complex protein production, aiming to accelerate the development and eventual market approval of Factor VIIa. The collaboration underscores the high unmet medical need in this area and the commitment of both companies to bring this novel therapy to patients more quickly​.